Literature DB >> 25649290

Dysregulated MicroRNA Expression and Chronic Lung Allograft Rejection in Recipients With Antibodies to Donor HLA.

Z Xu1, D Nayak1, W Yang2, G Baskaran3, S Ramachandran1, N Sarma1, A Aloush3, E Trulock3, R Hachem3, G A Patterson1, T Mohanakumar1,4.   

Abstract

The pathogenesis of chronic rejection, Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation (LT) is poorly understood. We hypothesized that development of antibodies to HLA (DSA) is associated with dysregulation of microRNA (miRNA) that predisposes BOS. Towards this, miRNA profiling of mononuclear cells from 10 stable LT (DSA(-) BOS(-) ), 10 LT with DSA(+) BOS(-) (DSA group) and 10 LT with DSA(+) BOS(+) (BOS group) were performed. Prediction by mirPath indicated that differential miRNAs in DSA(+) BOS(-) compared to stable are significantly up-regulated (relative fold >2, p < 0.05) for TGF-β and B cell receptor signal pathways. A total of seventy-four miRNAs were up-regulated and six miRNAs were down regulated in LT with DSA(+) BOS(+) when compared to stable (relative fold >2, p < 0.05). There was also significant enrichment of cell cycle and gap junction pathways. An inverse correlation between expression of two key miRNAs and their target genes were observed: miR-369-5p and miR-548d were down regulated in DSA(+) LT while their gene targets in TGF-β signal pathways were up-regulated. In addition, miR-628-5p and miR-134 were down regulated and their target genes (B cell development) were up-regulated. Therefore, we conclude that alloimmunity induced changes in miRNAs affecting the TGF-β and B cell receptor signal pathways play important roles in BOS development. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25649290      PMCID: PMC5607954          DOI: 10.1111/ajt.13185

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  39 in total

1.  Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  A Jaramillo; M A Smith; D Phelan; S Sundaresan; E Trulock; J Lynch; J Cooper; G A Patterson; T Mohanakumar
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  Functional microRNA targets in protein coding sequences.

Authors:  Martin Reczko; Manolis Maragkakis; Panagiotis Alexiou; Ivo Grosse; Artemis G Hatzigeorgiou
Journal:  Bioinformatics       Date:  2012-01-27       Impact factor: 6.937

3.  Smart pooling of mRNA samples for efficient transcript profiling.

Authors:  Raghunandan M Kainkaryam; Angela Bruex; Peter J Woolf; John Schiefelbein
Journal:  Methods Mol Biol       Date:  2012

4.  An obligatory role for lung infiltrating B cells in the immunopathogenesis of obliterative airway disease induced by antibodies to MHC class I molecules.

Authors:  N Fukami; S Ramachandran; M Takenaka; J Weber; V Subramanian; T Mohanakumar
Journal:  Am J Transplant       Date:  2012-01-10       Impact factor: 8.086

5.  Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection.

Authors:  J M Charpin; J Valcke; L Kettaneh; B Epardeau; M Stern; D Israël-Biet
Journal:  Transplantation       Date:  1998-03-15       Impact factor: 4.939

6.  De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.

Authors:  Trudie A Goers; Sabarinathan Ramachandran; Aviva Aloush; Elbert Trulock; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 7.  Human leukocyte antigen antibodies and chronic rejection: from association to causation.

Authors:  Paul I Terasaki; Junchao Cai
Journal:  Transplantation       Date:  2008-08-15       Impact factor: 4.939

8.  Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.

Authors:  Nils Lachmann; Paul I Terasaki; Klemens Budde; Lutz Liefeldt; Andreas Kahl; Petra Reinke; Johann Pratschke; Birgit Rudolph; Danilo Schmidt; Abdulgabar Salama; Constanze Schönemann
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

9.  Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montréal Lung Transplantation Group.

Authors:  A Magnan; J L Mege; J C Escallier; J Brisse; C Capo; M Reynaud; P Thomas; B Meric; L Garbe; M Badier; L Viard; P Bongrand; R Giudicelli; D Metras; P Fuentes; D Vervloet; M Noirclerc
Journal:  Am J Respir Crit Care Med       Date:  1996-04       Impact factor: 21.405

10.  Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in αβ and γδ T cells.

Authors:  Jan D Haas; Kiran Nistala; Franziska Petermann; Namita Saran; Vijaykumar Chennupati; Susanne Schmitz; Thomas Korn; Lucy R Wedderburn; Reinhold Förster; Andreas Krueger; Immo Prinz
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

View more
  17 in total

1.  Integrated analysis of transcription factor, microRNA and LncRNA in an animal model of obliterative bronchiolitis.

Authors:  Ming Dong; Xin Wang; Hong-Lin Zhao; Xing-Long Chen; Jing-Hua Yuan; Jiu-Yi Guo; Ke-Qiu Li; Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Exosomes expressing the self-antigens myosin and vimentin play an important role in syngeneic cardiac transplant rejection induced by antibodies to cardiac myosin.

Authors:  Monal Sharma; Wei Liu; Sudhir Perincheri; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Am J Transplant       Date:  2018-02-14       Impact factor: 8.086

3.  Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection.

Authors:  M Gunasekaran; Z Xu; D K Nayak; M Sharma; R Hachem; R Walia; R M Bremner; M A Smith; T Mohanakumar
Journal:  Am J Transplant       Date:  2016-07-16       Impact factor: 8.086

4.  MicroRNAs derived from urinary exosomes act as novel biomarkers in the diagnosis of intrahepatic cholestasis of pregnancy.

Authors:  Pei-Yue Jiang; Xiao-Jun Zhu; Ruo-An Jiang; Yi-Na Zhang; Liu Liu; Xiao-Fu Yang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  Combined treatment with sinomenine and acupuncture on collagen-induced arthritis through the NF-κB and MAPK signaling pathway.

Authors:  Minmin Xu; Shaofan Liu; Ruijie Wan; Yu Chen
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

6.  Tissue-associated self-antigens containing exosomes: Role in allograft rejection.

Authors:  Monal Sharma; Ranjithkumar Ravichandran; Sandhya Bansal; Ross M Bremner; Michael A Smith; T Mohanakumar
Journal:  Hum Immunol       Date:  2018-06-15       Impact factor: 2.850

7.  Role of Circulating MicroRNAs in the Immunopathogenesis of Rejection After Pediatric Lung Transplantation.

Authors:  Zhongping Xu; Wei Yang; Nancy Steward; Stuart C Sweet; Lara Danziger-Isakov; Peter S Heeger; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

Review 8.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

9.  Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis.

Authors:  Monal Sharma; Muthukumar Gunasekaran; Ranjithkumar Ravichandran; Cynthia E Fisher; Ajit P Limaye; Chengcheng Hu; John McDyer; Vaidehi Kaza; Ankit Bharat; Sofya Tokman; Ashraf Omar; Ashwini Arjuna; Rajat Walia; Ross M Bremner; Michael A Smith; Ramsey R Hachem; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2020-07-07       Impact factor: 10.247

Review 10.  Clinically relevant interpretation of solid phase assays for HLA antibody.

Authors:  Maria P Bettinotti; Andrea A Zachary; Mary S Leffell
Journal:  Curr Opin Organ Transplant       Date:  2016-08       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.